Status:
UNKNOWN
The Surveillance of Hepatocellular Carcinoma
Lead Sponsor:
Chinese PLA General Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-80 years
Brief Summary
Early detection of hepatocellular carcinoma is vita to the prognosis of patient. In this study, the occurrence and development of liver cancer were supervised by imaging examination, and the dysplasti...
Eligibility Criteria
Inclusion
- \- Patients with Hepatitis B and cirrhosis Accept regular imaging examination. Pathological diagnosis of liver cancer.
Exclusion
- \- Can't tolerate the enhanced imaging examination Poor medical compliance
Key Trial Info
Start Date :
January 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05286099
Start Date
January 15 2022
End Date
December 31 2023
Last Update
March 18 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100853
2
Chinese PLA general hospital
Beijing, China